Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening

被引:64
作者
Alebouyeh, M [1 ]
Moussavi, F [1 ]
Haddad-Deylami, H [1 ]
Vossough, P [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Dept Pediat Hematol Oncol, Shohada Med Ctr, Tehran Tajrish 15959, Iran
关键词
major beta-thalassemia; genetic screening; IVSII-1; mutation; Xmn1; polymorphism; hydroxyurea;
D O I
10.1007/s00277-003-0836-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Efforts have been undertaken to find an alternative approach to packed red cell transfusion (PRCT) in major beta-thalassemia. Augmentation of fetal hemoglobin (HbF) by hydroxyurea (HU) has been reported to be less effective in this condition as compared to sickle cell anemia due to molecular heterogeneity of the former disease. HU efficacy and its relation to Xmn1 polymorphism and IVSII-1 mutation was evaluated in major beta-thalassemics. Forty-five patients, M/F ratio 0.8, aged 6-33 years, received oral HU, 20 mg/kg per day, 4 days per week and daily1 mg folic acid. Thirty-six patients were PRCT dependent (group A) and nine independent (group B). The aim was to stabilize or increase pre-PRCT Hb over 10.0+/-0.5 g/dl and to reduce the need or cease the PRCT in group A and to increase Hb level and curb the ineffective erythropoesis, e.g., splenomegaly, facial bone deformity, in group B. HU was administered for at least 6 months (mean: 9 months) and discontinued in case of response failure. Screening for Xmn1 polymorphism and IVSII-1 mutation was carried out in most patients. In group A, 25 patients have become PRCT independent for a period of 2.5-7.3 years (mean: 4 years). The mean Hb, pre-HU 10.0 and post-HU 10.7 g/dl (range: 8.8-13.7 g/dl), mean serum ferritin pre- and post-HU was1877 and 525 ng/ml. The PRCT requirement was reduced in one patient, and ten patients did not respond. In group B HU has been given over 3.3 years (range: 2.8-4.8 years), Hb increased from 9.3 to 10.4/dl, and there was no tangible progression of ineffective erythropoesis. Responders in both groups expressed more comfort with this regimen. Xmn1 and IVSII-1 (homo- and/or heterozygosis) are relevant markers in most responding patients. Molecular determination of genetic markers in early childhood will help to identify candidates for pharmacological HbF switching by HU.
引用
收藏
页码:430 / 433
页数:4
相关论文
共 27 条
  • [1] Successful use of hydroxyurea in beta-thalassemia major
    Arruda, VR
    Lima, CSP
    Saad, STO
    Costa, FF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (13) : 964 - 964
  • [2] BLAU CA, HAEMATOLOGY TRENDS 9, P144
  • [3] BUNN HF, 1999, BLOOD, V9, P762
  • [4] GENOTYPE-PHENOTYPE CORRELATIONS IN BETA-THALASSEMIAS
    CAO, A
    GALANELLO, R
    ROSATELLI, MC
    [J]. BLOOD REVIEWS, 1994, 8 (01) : 1 - 12
  • [5] HYDROXYUREA AS TREATMENT FOR SICKLE-CELL-ANEMIA
    CHARACHE, S
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1991, 5 (03) : 571 - 583
  • [6] Hematological responses to hydroxyurea therapy in multitransfused thalassemic children
    Choudhry V.P.
    Lal A.
    Pati H.P.
    Arya L.S.
    [J]. The Indian Journal of Pediatrics, 1997, 64 (3) : 395 - 398
  • [7] Dedoussis GVZ, 2000, AM J HEMATOL, V64, P151, DOI 10.1002/1096-8652(200007)64:3<151::AID-AJH2>3.3.CO
  • [8] 2-O
  • [9] Hemoglobin switching protocols in Thalassemia - Experience with sodium phenylbutyrate and hydroxyurea
    Dover, GJ
    [J]. COOLEYS ANEMIA: SEVENTH SYMPOSIUM, 1998, 850 : 80 - 86
  • [10] Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia hemoglobin E disease
    Fucharoen, S
    Siritanaratkul, N
    Winichagoon, P
    Chowthaworn, J
    Siriboon, W
    Muangsup, W
    Chaicharoen, S
    Poolsup, N
    Chindavijak, B
    Pootrakul, P
    Piankijagum, A
    Schechter, AN
    Rodgers, GP
    [J]. BLOOD, 1996, 87 (03) : 887 - 892